Outcome measures for artificial pancreas clinical trials: A consensus report

David M. Maahs, Bruce A. Buckingham, Jessica R. Castle, Ali Cinar, Edward R. Damiano, Eyal Dassau, J. Hans De Vries, Francis J. Doyle, Steven C. Griffen, Ahmad Haidar, Lutz Heinemann, Roman Hovorka, Timothy W. Jones, Craig Kollman, Boris Kovatchev, Brian L. Levy, Revital Nimri, David N. O'Neal, Moshe Philip, Eric RenardSteven J. Russell, Stuart A. Weinzimer, Howard Zisser, John W. Lum

Research output: Contribution to journalArticlepeer-review

185 Scopus citations


Research on and commercial development of the artificial pancreas (AP) continue to progress rapidly, and the AP promises to become a part of clinical care. In this report, members of the JDRF Artificial Pancreas Project Consortium in collaboration with thewider AP community 1) advocate for the use of continuous glucose monitoring glucosemetrics as outcomemeasures in AP trials, in addition to HbA1c, and 2) identify a short set of basic, easily interpreted outcome measures to be reported in AP studies whenever feasible. Consensus on a broader range of measures remains challenging; therefore, reporting of additional metrics is encouraged as appropriate for individual AP studies or study groups. Greater consistency in reporting of basic outcome measures may facilitate the interpretation of study results by investigators, regulatory bodies, health care providers, payers, and patients themselves, thereby accelerating the widespread adoption of AP technology to improve the lives of people with type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)1175-1179
Number of pages5
JournalDiabetes care
Issue number7
StatePublished - Jul 1 2016

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing


Dive into the research topics of 'Outcome measures for artificial pancreas clinical trials: A consensus report'. Together they form a unique fingerprint.

Cite this